Aktienanalyse zu Lifeward Ltd (LFWD)LFWDLifeward Ltd

Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AN industry).

ReWalk Robotics Ltd appears to be a good buy right now, primarily due to its current price of $7.46, which is significantly below the analyst price target of $10, indicating a potential upside of 34%. Additionally, the company's recent revenue growth of 11% year-over-year in ReWalk personal exoskeleton sales suggests positive momentum. However, investors should be cautious of the high net loss of $11.5 million reported in Q2 2026, which represents a risk to profitability.